CRVO
MCID: CNT016
MIFTS: 53

Central Retinal Vein Occlusion (CRVO)

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Central Retinal Vein Occlusion

MalaCards integrated aliases for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 58 54 15 71
Crvo 58

Characteristics:

Orphanet epidemiological data:

58
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:2450
ICD9CM 34 362.35
MeSH 43 D012170
NCIt 49 C118859
SNOMED-CT 67 68478007
ICD10 32 H34.81
ICD10 via Orphanet 33 H34.8
UMLS via Orphanet 72 C0154841
Orphanet 58 ORPHA411527
UMLS 71 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to macular retinal edema and neovascular glaucoma. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and PI3K-Akt signaling pathway. The drugs Triamcinolone and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are glaucoma and macular degeneration

Wikipedia : 74 The central retinal vein is the venous equivalent of the central retinal artery and, like that blood... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 31.7 VEGFA SERPINF1 PGF IL6
2 neovascular glaucoma 30.9 VEGFA PLG PGF
3 rubeosis iridis 30.8 VEGFA PLG
4 polycythemia 30.8 VEGFA JAK2 F5
5 arteritic anterior ischemic optic neuropathy 30.8 MTHFR F5 F2
6 amaurosis fugax 30.7 MTHFR F5
7 homocysteinemia 30.7 VWF SERPINC1 MTHFR F5 F2 APOH
8 retinal vein occlusion 30.7 VEGFA SERPINF1 SERPINC1 MTHFR LOXL1 IL6
9 fainting 30.5 VWF F8
10 macular holes 30.5 VEGFA SERPINF1 PLG
11 microvascular complications of diabetes 5 30.4 VEGFA SERPINF1 PLG PGF
12 raynaud phenomenon 30.4 VWF APOH
13 syphilis 30.3 IL6 F2 APOH
14 hypopyon 30.3 VEGFA IL6
15 leukostasis 30.3 VEGFA SERPINF1 IL6
16 diabetic macular edema 30.3 VEGFA SERPINF1 PGF IL6
17 cavernous sinus thrombosis 30.3 SERPINC1 F3 F2
18 exanthem 30.3 VEGFA IL6 F3 F2
19 branch retinal artery occlusion 30.3 VEGFA SERPINC1 PLG MTHFR F2
20 catastrophic antiphospholipid syndrome 30.2 MTHFR F5 F3 APOH
21 papilledema 30.2 VEGFA SERPINC1 F3 F2 APOH
22 nephrosclerosis 30.1 VEGFA MTHFR F3 F2
23 hemolytic-uremic syndrome 30.1 VWF SERPINC1 F3 F2
24 endophthalmitis 30.0 VEGFA PLG PGF IL6
25 deficiency anemia 30.0 SERPINC1 JAK2 IL6 G6PD
26 hemoglobinuria 30.0 SERPINC1 G6PD F2
27 protein c deficiency 30.0 SERPINC1 MTHFR F5 F2 APOH
28 retinal vascular disease 29.9 VEGFA SERPINF1 PLG PGF MTHFR IL6
29 eisenmenger syndrome 29.9 VWF PLAT
30 cataract 29.9 VEGFA SERPINF1 MTHFR LOXL1 IL6 G6PD
31 purpura 29.9 VWF SERPINC1 IL6 F3 F2 APOH
32 angina pectoris 29.9 PLAT IL6 F3
33 eye disease 29.8 VEGFA SERPINF1 PGF LOXL1 IL6
34 polycythemia vera 29.8 VWF JAK2 F5 F2
35 factor xii deficiency 29.7 VWF SERPINC1 F5 F3 APOH
36 thrombotic thrombocytopenic purpura 29.7 VWF SERPINC1 PLAT F3 APOH
37 sneddon syndrome 29.7 SERPINC1 F8 F5 F2 APOH
38 sickle cell anemia 29.7 VWF MTHFR IL6 G6PD F2
39 severe pre-eclampsia 29.7 VEGFA SERPINC1 PGF F5 APOH
40 protein s deficiency 29.7 SERPINC1 MTHFR F8 F5 F3 F2
41 nonarteritic anterior ischemic optic neuropathy 29.7 VEGFA SERPINC1 MTHFR G6PD F5 F2
42 intracranial hypertension 29.6 SERPINC1 MTHFR F5 F3 F2 APOH
43 respiratory failure 29.6 IL6 G6PD F3 F2
44 hemolytic anemia 29.5 VWF G6PD F3 F2 APOH
45 migraine with or without aura 1 29.4 PLG MTHFR IL6 F2 APOH
46 hemophilia b 29.4 VWF SERPINC1 F8 F3 F2
47 thrombocytosis 29.4 VWF SERPINC1 JAK2 IL6 F3 F2
48 central retinal artery occlusion 29.4 VEGFA SERPINC1 PLG PLAT MTHFR F2
49 eclampsia 29.3 VEGFA SERPINC1 PGF MTHFR IL6 F2
50 systemic lupus erythematosus 29.3 VWF VEGFA JAK2 IL6 F3 F2

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

Human phenotypes related to Central Retinal Vein Occlusion:

58 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glaucoma 58 Occasional (29-5%)
2 macular degeneration 58 Occasional (29-5%)
3 pigmentary retinopathy 58 Occasional (29-5%)
4 visual loss 58 Frequent (79-30%)
5 blurred vision 58 Occasional (29-5%)
6 papilledema 58 Frequent (79-30%)
7 large central visual field defect 58 Occasional (29-5%)
8 macular edema 58 Frequent (79-30%)
9 retinal vascular tortuosity 58 Frequent (79-30%)
10 epiretinal membrane 58 Occasional (29-5%)
11 cystoid macular edema 58 Very frequent (99-80%)
12 abnormal anterior eye segment morphology 58 Occasional (29-5%)
13 macular cotton wool spot 58 Very frequent (99-80%)
14 intraretinal hemorrhage 58 Very frequent (99-80%)
15 electronegative electroretinogram 58 Occasional (29-5%)
16 retinal neovascularization 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Central Retinal Vein Occlusion:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 APOH F2 F3 F5 F8 G6PD
2 cardiovascular system MP:0005385 10.36 F2 F3 F5 G6PD IL6 JAK2
3 growth/size/body region MP:0005378 10.29 F2 F3 F5 G6PD IL6 JAK2
4 hematopoietic system MP:0005397 10.27 F2 F3 F8 G6PD IL6 JAK2
5 immune system MP:0005387 10.23 F2 F3 F8 IL6 JAK2 PGF
6 mortality/aging MP:0010768 10.21 APOH F2 F3 F5 F8 G6PD
7 integument MP:0010771 10.17 F2 F3 F5 IL6 JAK2 LOXL1
8 digestive/alimentary MP:0005381 10.14 F2 IL6 LOXL1 PLAT PLG SERPINF1
9 embryo MP:0005380 10.13 F2 F3 F5 G6PD JAK2 PGF
10 nervous system MP:0003631 10.07 F2 F3 F5 G6PD IL6 LOXL1
11 liver/biliary system MP:0005370 9.95 F5 IL6 JAK2 MTHFR PLG SERPINC1
12 reproductive system MP:0005389 9.9 F2 F8 IL6 JAK2 LOXL1 MTHFR
13 neoplasm MP:0002006 9.8 F3 IL6 JAK2 PGF PLG VEGFA
14 respiratory system MP:0005388 9.61 F2 F3 IL6 JAK2 LOXL1 PGF
15 vision/eye MP:0005391 9.32 F3 IL6 LOXL1 MTHFR PGF PLAT

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Ranibizumab Approved Phase 4 347396-82-1 459903
8
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
9 Triamcinolone diacetate Phase 4
10 triamcinolone acetonide Phase 4
11 Triamcinolone hexacetonide Phase 4
12 Pharmaceutical Solutions Phase 4
13 Antineoplastic Agents, Immunological Phase 4
14 Anti-Bacterial Agents Phase 4
15 Antibiotics, Antitubercular Phase 4
16 Dexamethasone 21-phosphate Phase 4
17
protease inhibitors Phase 4
18 HIV Protease Inhibitors Phase 4
19 Gastrointestinal Agents Phase 4
20 Antineoplastic Agents, Hormonal Phase 4
21 Hormones Phase 4
22 Antiemetics Phase 4
23 Hormone Antagonists Phase 4
24 Angiogenesis Inhibitors Phase 4
25 glucocorticoids Phase 4
26 BB 1101 Phase 4
27 Anti-Inflammatory Agents Phase 4
28
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
29
Atorvastatin Approved Phase 3 134523-00-5 60823
30
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
31
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
34 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
35
Iodine Approved, Investigational Phase 3 7553-56-2 807
36
Povidone Approved Phase 3 9003-39-8
37
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
39
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
40
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
41 Insulin, Globin Zinc Phase 2, Phase 3
42 insulin Phase 2, Phase 3
43 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
44 Anticholesteremic Agents Phase 3
45 Immunologic Factors Phase 3
46 Immunosuppressive Agents Phase 3
47 Protective Agents Phase 2, Phase 3
48 Anesthetics Phase 3
49 Methylprednisolone Acetate Phase 2, Phase 3
50 Neuroprotective Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
2 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
3 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
6 Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis Completed NCT01448018 Phase 4 ranibizumab
7 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
8 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
9 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
10 A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months. Completed NCT01710839 Phase 4 0.5mg Ranibizumab
11 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
12 A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
13 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
14 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
15 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
16 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
17 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Recruiting NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
18 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
19 Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study. Not yet recruiting NCT04062370 Phase 4 Ranibizumab
20 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
21 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
22 Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO) Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
23 A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO) Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
24 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
25 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
26 A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia] Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
27 A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
28 A 3-month, Phase III, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Monthly Intravitreal Injections as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Branch or Central Retinal Vein Occlusion (RVO) Completed NCT01377597 Phase 3 ranibizumab
29 A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3 Ranibizumab;Dexamethasone implant and sham injections
30 A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00485836 Phase 3 Sham injection;Ranibizumab injection 0.3 mg;Ranibizumab injection 0.5 mg
31 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
32 A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Completed NCT01535261 Phase 3 Ranibizumab 0.5 mg/0.05 ml
33 Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab Completed NCT01198327 Phase 3 ranibizumab
34 The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Completed NCT00106132 Phase 3 Triamcinolone Acetonide
35 A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study Completed NCT00532142 Phase 2, Phase 3 Intravitreal Triamcinolone
36 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
37 Study of the Safety and Efficacy of Bevacizumab Intravitreal Injections for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
38 Phase II/III Multicentre Randomised Clinical Trial of Laser Treatment Plus 4 mg Intravitreal Triamcinolone Injection to Reduce Diabetic Macular Oedema Completed NCT00148265 Phase 2, Phase 3 Triamcinolone acetate
39 A Randomized, Double-masked Study With Intraocular Bevacizumab Compared With Intravitreal Ranibizumab in Patients With Persistent Diabetic Macular Edema or Persistent Active Neovascularisation Following Lasercoagulation Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
40 Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion Completed NCT00805064 Phase 3 triamcinolone and bevacizumab
41 Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO Completed NCT00493064 Phase 2, Phase 3 Nicotinic acid;Prednisolone acetate
42 Efficacy of an Intravitreal Dexamethasone Implant on Macular Function in Retinal Vein Occlusion Following Treatment With Intravitreal Anti-VEGF Injections. Completed NCT01449682 Phase 3 Ozurdex;Ozurdex
43 An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Recruiting NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
44 Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks. Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
45 Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema Active, not recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
46 An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Suspended NCT03810313 Phase 3 Brolucizumab 6 mg;Aflibercept 2 mg
47 "Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO." Terminated NCT00500045 Phase 2, Phase 3 nicotinic acid
48 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
49 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
50 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

40
Eye, Retina, Endothelial, Bone Marrow, Bone, Heart, Myeloid

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 2221)
# Title Authors PMID Year
1
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. 61 54
19967679 2010
2
Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein. 54 61
19734765 2009
3
Central retinal vein occlusion secondary to clomiphene treatment in a male carrier of factor V Leiden. 61 54
19371211 2009
4
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 61 54
19118700 2009
5
Central retinal vein occlusion with therapeutic level of anticoagulation. 54 61
19707484 2009
6
Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency (Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Vol. 42[4]). 61 54
18059510 2007
7
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. 61 54
18040240 2007
8
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 61 54
19668494 2007
9
Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. 61 54
17641719 2007
10
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 61 54
17700285 2007
11
[Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia]. 54 61
16848214 2006
12
Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. 54 61
16491037 2006
13
[Central retinal vein occlusion in a factor V leiden and G21210A prothrombin variant carrier]. 61 54
15389368 2004
14
Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. 61 54
15121372 2004
15
Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. 61 54
14707827 2003
16
Central retinal vein occlusion and renal cell carcinoma. 61 54
14644245 2003
17
Hyperhomocysteinemia in central retinal vein occlusion in young adults. 54 61
15513477 2003
18
Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion. 54 61
12598443 2003
19
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. 54 61
12470137 2002
20
Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation. 54 61
12383824 2002
21
Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation. 54 61
12022286 2002
22
Simultaneous bilateral central retinal vein occlusion associated with anticardiolipin antibodies in leukemia. 54 61
11476696 2001
23
Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. 54 61
11797310 2001
24
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. 54 61
11321143 2001
25
Activated protein C resistance is a risk factor for central retinal vein occlusion. 54 61
11059059 2000
26
Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. 54 61
10837386 2000
27
Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. 61 54
10634550 1999
28
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. 54 61
10634554 1999
29
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]. 54 61
10501988 1999
30
Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. 54 61
10392729 1999
31
Risk factors in central retinal vein occlusion and activated protein C resistance. 61 54
10230591 1999
32
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. 54 61
9596492 1998
33
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 61 54
9499769 1998
34
Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. 61 54
9402832 1997
35
Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion. 61 54
9372721 1997
36
Activated protein C resistance in patients with central retinal vein occlusion. 54 61
9486021 1997
37
Activated protein C resistance in central retinal vein occlusion. 54 61
9059288 1996
38
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. 61 54
8913121 1996
39
Activated protein C resistance in young adults with central retinal vein occlusion. 54 61
8703855 1996
40
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. 54 61
8703856 1996
41
Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. 54 61
8981710 1996
42
Hypoxic regulation of vascular endothelial growth factor in retinal cells. 61 54
7487623 1995
43
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 61 54
7540233 1995
44
Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. 61 54
8849546 1995
45
CENTRAL RETINAL VEIN OCCLUSION IN OTHERWISE HEALTHY CHILDREN AND ADOLESCENTS: Association With Multigenetic Variants of Thrombophilia. 61
31095065 2020
46
Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion. 61
32281001 2020
47
Relationship between retinal blood flow and cytokines in central retinal vein occlusion. 61
32503534 2020
48
PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial. 61
31157710 2020
49
The role of serum inflammation-based factors in Anti-VEGF treatment for macular edema secondary to retinal vein occlusion and its subtypes. 61
32506058 2020
50
Perineuritis or infiltration of optic nerve sheath? A presentation of diffuse large B cell Gastric lymphoma. 61
32461486 2020

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

Pathways related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 VWF VEGFA SERPINC1 PLG PLAT JAK2
2
Show member pathways
12.76 VWF VEGFA PGF JAK2 IL6
3 12.58 VEGFA PGF JAK2 IL6 F2
4
Show member pathways
12.57 SERPINC1 LOXL1 F8 F5 F3 F2
5
Show member pathways
11.99 PLG PLAT MTHFR IL6 F2
6
Show member pathways
11.76 VWF SERPINC1 PLG PLAT F8 F5
7 11.74 VEGFA JAK2 IL6
8 11.62 VEGFA JAK2 IL6 F3
9 11.39 VWF SERPINC1 PLG PLAT F8 F5
10 11.3 VEGFA PLG PLAT
11 11.26 PLG PLAT IL6
12
Show member pathways
10.7 VEGFA PGF
13 10.59 PLG PLAT

GO Terms for Central Retinal Vein Occlusion

Cellular components related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 VWF SERPINF1 SERPINC1 PLG PLAT G6PD
2 extracellular space GO:0005615 9.97 VEGFA SERPINF1 SERPINC1 PLG PLAT PGF
3 cell surface GO:0009986 9.83 VEGFA PLG PLAT F3 APOH
4 extracellular region GO:0005576 9.8 VWF VEGFA SERPINF1 SERPINC1 PLG PLAT
5 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 IL6 F8 F5 F2
6 platelet alpha granule lumen GO:0031093 9.65 VWF VEGFA PLG F8 F5
7 platelet alpha granule GO:0031091 9.4 VWF F5
8 collagen-containing extracellular matrix GO:0062023 9.28 VWF SERPINF1 SERPINC1 PLG PLAT LOXL1

Biological processes related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 VEGFA PGF JAK2 IL6 F2
2 cytokine-mediated signaling pathway GO:0019221 9.9 VEGFA JAK2 IL6 F3
3 response to hypoxia GO:0001666 9.81 VEGFA PLAT PGF MTHFR
4 cellular protein metabolic process GO:0044267 9.8 SERPINC1 PLG IL6 F5 F2
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.77 VEGFA JAK2 IL6
6 platelet activation GO:0030168 9.76 VWF IL6 F8 F2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 VEGFA JAK2 IL6
8 positive regulation of endothelial cell proliferation GO:0001938 9.71 VEGFA PGF F3
9 acute-phase response GO:0006953 9.65 IL6 F8 F2
10 platelet degranulation GO:0002576 9.63 VWF VEGFA PLG F8 F5 APOH
11 vascular endothelial growth factor signaling pathway GO:0038084 9.62 VEGFA PGF
12 induction of positive chemotaxis GO:0050930 9.61 VEGFA PGF
13 positive regulation of blood coagulation GO:0030194 9.61 F2 APOH
14 fibrinolysis GO:0042730 9.61 PLG PLAT F2
15 positive regulation of positive chemotaxis GO:0050927 9.58 VEGFA F3
16 plasminogen activation GO:0031639 9.58 PLAT APOH
17 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.56 VEGFA PLG
18 blood coagulation, intrinsic pathway GO:0007597 9.56 VWF F8 F2 APOH
19 regulation of blood coagulation GO:0030193 9.54 SERPINC1 F2 APOH
20 positive regulation of mast cell chemotaxis GO:0060754 9.52 VEGFA PGF
21 negative regulation of fibrinolysis GO:0051918 9.5 PLG F2 APOH
22 hemostasis GO:0007599 9.5 VWF SERPINC1 PLG F8 F5 F3
23 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.49 PLG PLAT
24 blood coagulation GO:0007596 9.28 VWF SERPINC1 PLG PLAT JAK2 F8

Molecular functions related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 VWF VEGFA SERPINC1 PGF JAK2 G6PD
2 protease binding GO:0002020 9.58 VWF SERPINC1 F3
3 copper ion binding GO:0005507 9.5 LOXL1 F8 F5
4 serine-type endopeptidase activity GO:0004252 9.46 PLG PLAT F3 F2
5 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA PGF
6 growth factor activity GO:0008083 9.26 VEGFA PGF IL6 F2
7 heparin binding GO:0008201 9.02 VEGFA SERPINC1 PGF F2 APOH

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....